Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.

March 16 (Reuters) - Structure Therapeutics' oral obesity drug aleniglipron delivered up to 16.3% weight loss when compared with a placebo after 44 weeks of treatment in a mid‑stage study, it said on ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.